Status:
RECRUITING
VasoStar Vibrational Guidewire System to Facilitate Crossing Coronary Artery Chronic Total Occlusions
Lead Sponsor:
VasoStar, LLC
Collaborating Sponsors:
Summa Health
Conditions:
Chronic Total Occlusion of Coronary Artery
Chronic Angina
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
The goal of this project is to provide an improvement in wire performance to expedite crossing difficult lesions in the coronary vasculature.
Detailed Description
This Early Feasibility Study (EFS) is proposed to evaluate the initial safety and efficacy of the VasoStar guidewire system to cross complex coronary vascular lesions in non-tortuous arterial segments...
Eligibility Criteria
Inclusion
- Male or female, over 18 years of age, presenting with at least one ischemia inducing lesion in a native coronary artery that is refractory to standard guidewire crossing. Chronic total occlusion (CTO) is defined as 100% coronary blockage for over a 3-month duration documented either by prior catheterization or by clinical evaluation
- Suitable candidate for non-emergent, coronary angioplasty
- Documented de-novo or restenotic coronary chronic total occlusion defined as a lesion with TIMI 0 flow for at least 90 days refractory to conventional guidewire crossing
- Left ventricle ejection fraction \> 20% within the last 12 months.
- For antegrade chronic total occlusion procedures, activated clotting time (ACT) should be \> 300 sec
- Chronic total occlusion in a non-tortuous arterial segment
- Voluntarily sign a Patient Informed Consent Form specific to the study.
- Physically and mentally willing to comply with all study requirements.
Exclusion
- Successful target lesion crossing with a conventional wire system prior to enrollment
- Prisoners.
- Pregnancy
- Patient has an active implantable.
- Extensive dissection created by refractory guidewire
- Severe ongoing congestive heart failure (New York Heart Association Class IV symptoms)
- Active infection
- Uncontrolled Hypertension (Systolic blood pressure \> 180 mm) at the time of the procedure
- History of severe reaction to contrast media
- Recent myocardial infarction (within 2 weeks)
- In-stent target lesion
- Severe cerebrovascular disease including history of prior stroke or transient ischemic attack within 1 month at the time of the procedure
- Saphenous vein graft (SVG) chronic total occlusion or an in-stent chronic total occlusion
- Short life expectancy due to other illnesses such as cancer or pulmonary, hepatic or renal disease
- Participation in another investigational protocol at the time of the procedure
Key Trial Info
Start Date :
June 10 2024
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 31 2026
Estimated Enrollment :
10 Patients enrolled
Trial Details
Trial ID
NCT06193954
Start Date
June 10 2024
End Date
December 31 2026
Last Update
September 16 2025
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Emory University
Atlanta, Georgia, United States, 30322
2
Summa Health
Akron, Ohio, United States, 44034